Hims & Hers opened a Canada generic semaglutide path and closed $402.5M of zero-coupon convertible debt. The update turns HIMS into a global expansion versus dilution proof test.
References
Sources used in this report
Company press releaseHims & Hers Expands GLP-1 Offering in Canada with Generic Semaglutide2026-05-21 · Canada generic semaglutide availability, C$149/month starting price, first international generic GLP-1 framing and Health Canada context.Company press releaseHims & Hers Health, Inc. Prices Upsized $350 Million Convertible Senior Notes Offering2026-05-18 · Initial convertible note pricing, zero-coupon structure, use of proceeds, Eucalyptus, fulfillment, technology and AI investment framing.SEC filingHims & Hers Health, Inc. Form 8-K2026-05-19 · Final $402.5M aggregate principal amount, settlement, conversion price, cap price and capped-call cost.Company press releaseHims & Hers Health, Inc. Reports First Quarter 2026 Financial Results2026-05-11 · Q1 revenue, Rest of World revenue, subscribers, gross margin, net loss, adjusted EBITDA, free cash flow and FY2026 guidance.Company press releaseHims & Hers Announces Agreement to Acquire Eucalyptus2026-02-12 · Strategic context for international expansion and the proposed Eucalyptus acquisition.